Y Intercept Hong Kong Ltd Purchases New Position in DexCom, Inc. $DXCM

Y Intercept Hong Kong Ltd acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 50,185 shares of the medical device company’s stock, valued at approximately $3,377,000.

Several other large investors have also modified their holdings of the stock. Andra AP fonden acquired a new position in DexCom in the second quarter valued at $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom in the 2nd quarter valued at about $26,000. SJS Investment Consulting Inc. grew its stake in DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. acquired a new position in DexCom during the third quarter worth approximately $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of DexCom in the second quarter valued at approximately $45,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on DXCM shares. Stifel Nicolaus started coverage on shares of DexCom in a research note on Tuesday, October 21st. They set a “buy” rating and a $85.00 price target for the company. Barclays lowered DexCom from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $80.00 to $71.00 in a report on Monday, January 12th. The Goldman Sachs Group reduced their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research note on Wednesday, October 1st. Citigroup reaffirmed a “buy” rating and set a $77.00 price objective (up from $75.00) on shares of DexCom in a research report on Thursday, December 11th. Finally, Wells Fargo & Company set a $93.00 target price on DexCom and gave the company an “overweight” rating in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.30.

Insider Activity at DexCom

In other DexCom news, Director Richard Alexander Collins sold 2,906 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the completion of the transaction, the director owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. This trade represents a 7.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is owned by corporate insiders.

DexCom Trading Down 0.3%

NASDAQ:DXCM opened at $73.15 on Tuesday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $93.25. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The stock has a fifty day moving average price of $66.71 and a two-hundred day moving average price of $70.98. The stock has a market capitalization of $28.53 billion, a price-to-earnings ratio of 40.64, a PEG ratio of 1.31 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the prior year, the firm posted $0.45 EPS. The company’s revenue was up 21.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.